Doma Perpetual Capital Management LLC
In its 13F for Q1 2025 (holdings as of March 31, 2025, filed May 15, 2025), Doma Perpetual Capital Management LLC reported 10 stock positions worth $254.4 million. Its top holding was Pacira Biosciences (PCRX) at 17.6% of the portfolio, followed by Davita (DVA, 17.3%) and Inmode (INMD, 15.6%). Compared with Q4 2024, it opened 2 new positions, added to 4 and reduced 2. The biggest buy was Davita (DVA, shares +172%) and the biggest sale Sirius XM (SIRI, shares −5%).
- Most Recent 13F
- Q2 2026
- Location
- Miami, FL
- CIK
- 0001962221
- Portfolio Value
- $254.4M (Q1 2025)
- SEC Filing
- 0001172661-25-002053 ↗ filed May 15, 2025
Holdings Value
Holdings 10 stocks · $254.4M
| PCRX Pacira Biosciences Inc. | 17.62% | 1,804,069 | $44.8M | Add +3.2% |
| DVA Davita Inc. | 17.34% | 288,360 | $44.1M | Add +172.3% |
| INMD Inmode Ltd. | 15.62% | 2,239,323 | $39.7M | No change |
| BBD Banco Bradesco-ADR | 12.78% | 14,580,430 | $32.5M | No change |
| NSSC Napco Security Technologies | 10.64% | 1,175,655 | $27.1M | Add +53.4% |
| SIRI Sirius XM Holdings Inc. | 10.27% | 1,158,398 | $26.1M | Reduce -5.2% |
| HIFS Hingham Institution for SVGS | 8.18% | 87,547 | $20.8M | Reduce -2.6% |
| AFYA Afya Ltd. Class A | 4.17% | 592,220 | $10.6M | Add +4.4% |
| PLGO Pelagos Insurance Capital LT filed as FIDELIS INSURANCE HOLDINGS L | 2.97% | 466,085 | $7.6M | New |
| IMXI International Money Express | 0.40% | 81,526 | $1.0M | New |
Portfolio Sells Q4 2024 → Q1 2025
Portfolio Buys Q4 2024 → Q1 2025
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 13 | $430.8M | PCRX, NOMD, MBIN, INMD, HIFS |
| Q1 2026 | 11 | $372.4M | PCRX, DVA, MBIN, INMD, AFYA |
| Q4 2025 | 12 | $355.6M | PCRX, INMD, MBIN, NOMD, DVA |
| Q3 2025 | 12 | $297.8M | PCRX, NSSC, DVA, INMD, SIRI |
| Q2 2025 | 10 | $264.0M | BBD, PCRX, DVA, NSSC, INMD |
| Q1 2025 | 10 | $254.4M | PCRX, DVA, INMD, BBD, NSSC |
| Q4 2024 | 8 | $201.0M | INMD, PCRX, SIRI, BBD, NSSC |
| Q3 2024 | 8 | $198.0M | INMD, BBD, NSSC, SIRI, PCRX |
| Q2 2024Amended | 9 | $215.6M | DVA, INMD, PCRX, BBD, LSXMK |
| Q1 2024Amended | 9 | $150.3M | DVA, LSXMK, PCRX, INMD, NSSC |